The agreement with Lee's Pharmaceutical represents a significant revenue opportunity for Windtree Therapeutics. The potential for earning up to $138.35 million in milestone payments is likely to be viewed positively by investors, potentially leading to an increase in the stock price in the short term. The deal expands Windtree's commercial presence in Asia, which is a positive development for the company's growth strategy.